Great news!
See this thread which highlights Prof Andersson's extensive network ... https://hotcopper.com.au/posts/41821048/single
He's ideally suited for ensuring a maximum number of sites are recruited for the two referenced AML trials.
Professor Andersson is experienced with progressing drugs through FDA approval.
Here's some analysis of the potential value of the AML pathways ...
The very, very important thing to understand is AML works.
- In November I identified a $0.47 price target for the Priority Review Voucher. See https://hotcopper.com.au/posts/41433448/single
- The 3 AML pathways combined have a revenue potential of AUD $1.54B
See https://hotcopper.com.au/posts/41986789/single
Listen to the AGM video, with particular attention to the part from 10 minutes in.
Also listen to the podcast.
Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Ann: Prof Borje Andersson appointed as Non-Executive Director, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
-0.010(0.81%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.14 | $381.6K | 320.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2171 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.17 |
Change
-0.010 ( 5.54 %) |
||||
| Open | High | Low | Volume | ||
| $1.23 | $1.23 | $1.14 | 48407 | ||
| Last updated 15.52pm 03/05/2024 ? | |||||
| RAC (ASX) Chart |